122 results
424B3
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement
4:53pm
and accounting. The audit report covering the December 31, 2023 consolidated financial statements contains an explanatory paragraph that states the Company
424B5
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement for primary offering
4:52pm
, and upon the authority of said firm as experts in accounting and auditing. The audit report covering the December 31, 2023 consolidated financial
424B3
t5mt53uc5tx3zkg
2 Feb 24
Prospectus supplement
12:00am
8-K
EX-10.2
46zanqy5
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
424B4
y1q5xmb7oxg 6f9t
2 Nov 23
Prospectus supplement with pricing info
9:00am